INVITED COMMENTARY

Phenotypic Properties of Preneoplastic Rat Liver Lesions and Applications to Detection of Carcinogens and Tumor Promoters
The paper "Phenotypic Properties of Preneoplastic Rat Liver Lesions and Applications to Detection of Carcinogens and Tumor Promoters" (7) , which has been recognized as one of the top 10 most frequently ciied papers published in the past 25 yr of Toxicologic Patliology, was presented in 1982 at a symposium of the Society of Toxicologic Pathologists on Rodent Liver Nodules: Significance to Human Cancer Risk. I described observations on the quantification of hepatocellular altered foci (HAF) in rodent liver as evidence of the initiating activity of an administered chemical or of the promoting activity of a chemical administered after an initiating agent. This line of investigation grew out of the first carcinogenicity studyin which I participated while in the laboratory of John Weisburger of the Chemical Carcinogen Screening Unit at the National Cancer Institute. In that study (15), 8hydroxyquinoline was administered with 2-acetyloaminofluorene to determine the effect on hepatocarcinogenesis. Unexpectedly, 8-hydroxyquinoline, acting as a chelating agent, increased iron absorption and produced widespread siderosis. In the siderotic livers, small cellular foci devoid of iron storage accompanied the formation of tumors, which also did not store iron. Further experiments revealed that these focal lesions were induced within a few weeks by several hepatocarcinogens (14) . After moving to the Fels Institute at Temple University, I conducted an experiment, in collaboration with Emanuel Farber, that showed that the foci were resistant to cytotoxic effects of carcinogens and were proliferative (13), further supporting their preneoplastic nature. I then hypothesized that if these lesions were precursors of neoplasms and if promoters acted to facilitate the development of initiated cells into neoplasms, as proposed by Berenblum (l), then promoters should enhance the development of these foci. Experiments revealed that administration of the liver tumor promoter phenobarbital after 2-acetylaminofluorene produced enhancement of foci. These findings were presented at the symposium on Mechanisms of Tumor Promotion and Carcinogenesis organized by the Biology Division of the Oak Ridge National Laboratory (6) and were published in greater detail later (5) . Subsequently, these iron-storage-deficient foci were demonstrated to have other phenotypic abnormalities (7), and hence are referred to as HAE With the collaboration of a number of coworkers, a variety of initiating and promoting agents was studied in rats and mice to assess the utility of measurement of HAF as an indicator of hepatocarcinogenic effects. These findings were later presented at a 1989 symposium organized by the National Toxicology Program on the Significance of Foci of Cellular Alteration in the Rat Liver, the proceedings of which were published in Toxicologic Patliology (8) . At that symposium, I advanced 2 ideas that were not generally accepted at the time: "a chemical that produces foci will, in 2-year study, induce liver tumors," and "[HAF] can be used to establish a no effect level for a hepatocarcinogen" (3). Subsequent developments have supported these suggestions.
Recently, a working group of the International Agency for Research on Cancer, for which I chaired the subgroup on animal studies, reviewed the utility of short-and'medium-term assays to assess carcinogenic activity (2) . The working group concurred that induction of preneoplastic lesions, including HAF (9), was a valid indicator of potential carcinogenic activity. In my own laboratory, the most recent application of this approach was the demonstration that the antiestrogen tamoxifen produced initiation in rat liver measured as induction of HAF (1 l) , which corresponds to the previously reported hepatocarcinogenicity (lo). Thus, as described in the 2 papers in Toxicologic Parliology (7, 8) the identification of initiation as manifested by induction of HAF would have been an accurate predictor of the carcinogenicity of tamoxifen had this been done as part of the development of the medicine.
We have also been using HAF in an effort to identify thresholds for DNA-reactive hepatocarcinogens. In a series of studies on quantitative exposure-response studies in rat hepatocarcinogenesis (4, 12) , we have documented that exposure to low levels of 2-acetylaminofluorene and diethylnitrosamine produces sublinearities for production of DNA adducts and HAF and elicits only a marginal 452 0192-6233/9853.00+$0.00 at SAGE PUBLICATIONS on December 9, 2012 tpx.sagepub.com Downloaded from vol. 26, NO. 3, 1998 COMMENTARY 453 incidence of liver tumors even with phenobarbital promotion. In current studies, using even lower doses, we have identified exposure levels that are subcarcinogenic. Accordingly, we predict that exposures that do not produce HAF will be nontumorigenic and exposures that do not produce adducts will not produce HAF or tumors. Eventually, such studies will establish thresholds even for genotoxic carcinogens. This subject will be reviewed at the Third International Conference of the International Federation of Societies of Toxicologic Pathology to be held in Cambridge, UK, in August 1998.
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